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ABSTRACT
The antifungal activity of curcumin against seven Candida species was studied by investigating the growth of 200 clinical isolates from patients
with fungal infections. The MICs of curcumin against Candida species were in the range of 32 to 128 µg/mL. The interaction of curcumin with amphotericin B or fluconazole against these fungi was determined by FIC index and % reduction in turbidity. Synergistic effect was shown in all combinations of curcumin and amphotericin B; whereas both synergistic and additive effects were observed in the combinations of curcumin and fluconazole.
This evidence suggests that when curcumin is combined with amphotericin B or fluconazole, it could provide greater fungicidal effects for the treatment of systemic fungal infections such as candidiasis and candidemia.
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INTRODUCTION
Candidiasis and candidemia are very common nosocomial fungal infections occurring in many hospitals.
Immunocompromised patients such as those with organ
transplants, cancer, human immunodeficiency virus (HIV)
infection or prolonged antibiotic treatments are susceptible to
fungal infections(1-3). These fungal infections might be fatal if
antifungal treatment is not prescribed. The common isolates
of candidiasis or candidemia are Candida albican, C. krusei,
C. glabrata, C. tropicalis, and C. guilliermondii, in which C.
albican is the most common; however, C. krusei and C.
glabrata have become increasingly important for hospitalized patients(2-4).
Amphotericin B belongs to the class of polyenes and is
a clinically popular antifungal agent. However, the clinical
use of amphotericin B is limited because of severe adverse
reactions such as diarrhea, malnutrition and progressive renal
toxicity(5-8). Azole compounds such as fluconazole (FCZ),
itraconazole (ICZ) are another class of antifungal agents used
for systemic fungal infections. These azoles are less toxic
than amphotericin B(7,8); however, some side effects of azoles
have been reported(9). In order to cure fungal infections successfully and to lower the dose of amphotericin B or azoles,
there is a need for the development of less toxic antifungal
agent, or to find one that is able to work with amphotericin B
or azoles additively or synergistically.
Curcumin, a yellow phenolic compound isolated from
turmeric (Curcuma longa), is responsible for the yellow color
of turmeric and curry. Based on its safe property, it has long
been used as a spice, food preservative and food coloring
agent in India and Southeast Asia(10,11). The content of cur* Author for correspondence. Tel: 04-4730022 ext. 1753;
Fax: 04-4739030; E-mail: mcyin@mercury.csmc.edu.tw

cumin in turmeric is 1-5% (or 4-8% of dry weight); and 40%
in turmeric oleoresin(11). Many studies have proven that curcumin has several important pharmacological properties such
as antioxidant, antimutagenic and antitumor activities(12-14).
Therefore, it is being evaluated as a chemopreventive agent
by the National Cancer Institute. Li et al.(15) indicated that
curcumin could block HIV-1 replication by inhibiting the
activity of its long terminal repeat; moreover, curcumin could
work with a reverse transcriptase inhibitor (e.g. dideoxyinosine) on HIV-1 synergistically. Although curcumin is a potent
anti-viral agent(15,19), it remains unknown whether curcumin
is an antifungal agent for Candida species.
This study was aimed to assay the in vitro inhibitory
effect of curcumin against seven Candida species. The interactions of curcumin with amphotericin B or fluconazole
against these fungi were also studied.

MATERIALS AND METHODS
I. Fungi Strains and Medium
Seven Candida species (Candida albican, C. krusei, C.
tropicalis, C. kefyr, C. guilliermondii, C. parapsilosis, C.
glabrata) were isolated from patients with fungal infections
such as candidiasis or candidemia in the Chungshan Hospital
(Taichung, Taiwan). A total of 200 isolates were tested in this
study. All isolates were identified by conventional methods(16). All cultures were routinely maintained on Sabouraud
dextrose agar (Difco, Detroit, MI) at 25˚C before use.
II. Antifungal Agents
Curcumin was purchased from Sigma Chem. Co. (St.
Louis, MO). Amphotericin B (AMB) and fluconazole (FCZ)
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were prepared from pharmaceutical solutions in sterile water.
All solutions were filtered through 0.22 µM filter for sterilization.
III. Antimicrobial Assays
All agents were further diluted with RPMI 1640 medium (1:5, v/v). The broth macrodilution method was performed as described in National Committee for Clinical
Laboratory Standards (NCCLs) document M27-A(17). The
final inoculum was 2 × 103 CFU/mL and was confirmed by
plating 10 and 100 µL from the agent-free control tube onto
Sabouraud dextrose agar. The final volume was 1 mL. The
agent concentrations ranged from 256 to 0.0625 µg/mL.
Agent-free and fungi-free controls were included. The turbidity was measured at 530 nm by a spectrophotometer after
48 hr incubation at 35˚C in RPMI 1640 medium containing
0.165 M morpholinepropanesulfonic acid (MOPS) (pH 7.0).
The MIC was defined as the concentration which produced
an 80% reduction in turbidity, compared with that of controls.
According to the standard of NCCLs, the isolates were classified as susceptible if the MIC was ≤ 8 µg/mL; resistant if
the MIC was ≥ 64 µg/mL; susceptible but dose dependent if
the MIC was 8~64 µg/mL.
IV. Interaction of Curcumin with AMB or FCZ
The effects of combinations of amphotericin B or fluconazole with curcumin were evaluated by the checkerboard
method recommended by the NCCLs. One hundred µ L
aliquots of each drug at 10X the targeted final concentration
was used. Drug interaction was classified as synergistic,
additive or less-than-additive based on the fractional
inhibitory concentration (FIC) index, which is the sum of
FICs for each drug. The FIC of each drug was calculated as
the MIC of this drug in combined treatment divided by that of
the drug used alone. Drug-drug interactions are considered
synergistic if the FIC index was less than 1.0; additive if the
FIC was equal to 1.0; less-than-additive if the FIC index was
greater than 1.0. The interaction of curcumin with amphotericin B or fluconazole were examined by combining 0.25,
0.5, 0.75 MIC AMB (or FCZ) with curcumin at various MIC
values. The total MIC values in each combination were ≤ 1.
The final inoculum was 2 × 103 CFU/mL and the final volume was 1 mL. The turbidity of each combination was then
measured at 530 nm by a spectrophotometer after 48 hr incu-

bation at 35˚C in RPMI 1640 medium containing 0.165 M
(MOPS) (pH 7.0).

RESULTS AND DISCUSSION
The MICs of curcumin, amphotericin B and fluconazole
against Candida species are presented in Table 1. The
inhibitory effect of amphotericin B and fluconazole against
these Candida species has been studied(9,18). It was reported
that the MICs of amphotericin B and fluconazole were in the
range of 0.125-2 and 0.25-128 µg/mL, respectively. The
observed MICs (Table 1) of amphotericin B and fluconazole
in our present study were close to those of previous studies. It
was reported that fluconazole is inactive to C. krusei and the
MIC90 was 128 µg/mL(9). In our present study, the MIC80 of
fluconazole against C. krusei was 128 µg/mL. This result
supported that C. krusei was resistant to fluconazole.
The MIC80 of curcumin against the tested Candida
species were in the range of 32-128 µ g/mL (Table 1).
Curcumin was found to be weaker when compared with
amphotericin B or fluconazole. Although curcumin is a food
component and amounts of up to 100 mg/day have been
taken by certain people for long time(11), it remains unknown
whether curcumin could achieve the blood concentrations of
32-128 µg/mL via oral or i.v. administration. Moreover, further in vivo studies are needed to prove the safety of curcumin at these concentrations. The interaction of curcumin with
amphotericin B or fluconazole, determined as FIC index, is
presented in Table 2. All interactions of curcumin and
amphotericin B were synergistic because the FIC indexes
were less than 1. Several interactions of curcumin with fluconazole were additive because the FIC indexes were equal
to 1. These observed synergistic effects showed that the interaction of curcumin with either amphotericin B or fluconazole
exhibited greater effect against Candida species. Both synergistic and additive effects observed in these combinations
also suggest that the dosage of amphotericin B or fluconazole
could be decreased. The interactions of curcumin with
amphotericin B or fluconazole, determined as % reduction in
turbidity, are presented in Tables 3 and 4. Many combinations
of amphotericin B (or fluconazole) plus curcumin demonstrated ≥ 80% reduction in turbidity. In this study, the MIC of
each agent against each tested fungi was defined as 80%
reduction in turbidity. Therefore, the greater turbidity reduction observed in these combinations suggests that these combinations exhibited greater anti-Candidal effects than each

Table 1. MIC (µg/mL) of curcumin, amphotericin B (AMB) and fluconazole (FCZ) against Candida species
Fungal species (number of isolates)
Curcumin
AMB
FCZ
C. albican (52)
32 ± 2
0.125 ± 0.06
0.5 ± 0.5
C. krusei (30)
128 ± 8
1.0 ± 0.5
128.0 ± 16.0
C. tropicalis (27)
48 ± 2
0.125 ± 0.06
1.0 ± 0.25
C. kefyr (25)
96 ± 4
0.25 ± 0.125
4.0 ± 0.5
C. guilliermondii (21)
108 ± 8
0.5 ± 0.25
32.0 ± 2.0
C. parapsilosis (20)
64 ± 4
0.25 ± 0.125
2.0 ± 0.5
C. glabrata (25)
80 ± 4
0.5 ± 0.25
16.0 ± 2.0
MIC was determined according to the macrodilution method recommended by NCCLs and was defined as 80% reduction in turbidity. The concentration is expressed as mean ± standard deviation (n=5).
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Table 2. Interaction of curcumin with amphotericin B (AMB) or fluconazole (FCZ), determined as FIC index
FIC
FIC
Fungal species
AMB
Curcumin
Index
FCZ
Curcumin
Index
(number of isolates)
C. albican (52)
0.5
0.25
0.75
0.25
0.5
0.75
C. krusei (30)
0.75
0.125
0.875
0.5
0.5
1
C. tropicalis (27)
0.5
0.25
0.75
0.25
0.5
0.75
C. kefyr (25)
0.25
0.5
0.75
0.75
0.25
1
C. guilliermondii (21)
0.25
0.5
0.75
0.5
0.5
1
C. parapsilosis (20)
0.5
0.25
0.75
0.25
0.5
0.75
C. glabrata (25)
0.5
0.25
0.75
0.25
0.625
0.875
The interaction of curcumin with AMB or FCZ was evaluated by the checkerboard method recommended by the NCCLs and expressed as the sum
of fractional inhibitory concentration (FIC) index for each agent. The FIC of each agent is calculated as the MIC of this agent in combination divided by the MIC of this agent alone.
Table 3. Interaction of curcumin with amphotericin B (AMB), determined as % reduction in turbidity.
AMB
AMB
AMB
0.75 MIC
0.5 MIC
0.25 MIC
Fungal species
Curcumin
Curcumin
Curcumin
(numberof isolates)
0.0625 (MIC) 0.125
0.25
0.125
0.25
0.5
0.25
0.5
0.75
C. albicans (52)
80 ± 3
90 ± 2
97 ± 3
71 ± 4
80 ± 3
96 ± 2
64 ± 4
85 ± 2
96 ± 2
C. krusei (30)
68 ± 4
79 ± 3
90 ± 2
62 ± 5
77 ± 2
88 ± 2
57 ± 5
75 ± 3
89 ± 3
C. tropicalis (27)
78 ± 2
87 ± 2
96 ± 2
68 ± 4
79 ± 3
94 ± 2
67 ± 3
84 ± 2
95 ± 2
C. kefyr (25)
75 ± 3
84 ± 2
93 ± 2
67 ± 3
76 ± 3
91 ± 3
57 ± 5
81 ± 3
93 ± 3
C. guilliermondii (21)
70 ± 3
82 ± 3
92 ± 3
63 ± 2
74 ± 2
93 ± 2
55 ± 4
80 ± 5
90 ± 1
C. parapsilosis (20)
78 ± 3
84 ± 2
95 ± 3
69 ± 4
80 ± 3
95 ± 2
62 ± 3
85 ± 3
94 ± 2
C. glabrata (25)
72 ± 4
82 ± 2
94 ± 2
66 ± 4
78 ± 3
92 ± 1
59 ± 4
83 ± 2
92 ± 3
AMB at 0.25, 0.5, 0.75 MIC was combined with curcumin at various MIC values. The total MIC values in each combination were ≤ 1. The turbidity of each combination was measured and expressed as mean ± standard deviation (n=5).
Table 4. Interaction of curcumin with fluconazole (FCZ), determined as % reduction in turbidity
FCZ
FCZ
FCZ
0.75 MIC
0.5 MIC
0.25 MIC
Fungal species
Curcumin
Curcumin
Curcumin
(number of isolates)
0.0625 (MIC) 0.125
0.25
0.125
0.25
0.5
0.25
0.5
0.75
C. albicans (52)
77 ± 3
85 ± 2
90 ± 3
68 ± 4
76 ± 3
91 ± 2
61 ± 4
82 ± 3
91 ± 2
C. krusei (30)
57 ± 4
73 ± 2
82 ± 2
53 ± 4
68 ± 2
80 ± 2
50 ± 5
71 ± 2
82 ± 1
C. tropicalis (27)
76 ± 4
84 ± 3
91 ± 3
64 ± 3
72 ± 2
87 ± 3
59 ± 3
78 ± 3
90 ± 3
C. kefyr (25)
73 ± 2
80 ± 2
88 ± 3
61 ± 3
69 ± 2
86 ± 3
54 ± 4
75 ± 3
87 ± 3
C. guilliermondii (21)
68 ± 3
76 ± 4
85 ± 2
59 ± 4
88 ± 3
85 ± 2
51 ± 2
74 ± 2
86 ± 2
C. parapsilosis (20)
75 ± 3
80 ± 3
87 ± 3
67 ± 3
78 ± 2
88 ± 1
58 ± 2
83 ± 2
88 ± 3
C. glabrata (25)
70 ± 3
78 ± 2
86 ± 2
65 ± 4
75 ± 2
86 ± 2
53 ± 3
80 ± 3
87 ± 2
FCZ at 0.25, 0.5, 0.75 MIC was combined with curcumin at various MIC values. The total MIC values in each combination were ≤ 1. The turbidity of each combination was measured and expressed as mean ± standard deviation (n=5).

agent at 1 MIC. The various combinations included 0.75
MIC AMB (or FCZ) plus 0.25 MIC curcumin; 0.5 MIC AMB
(or FCZ) plus 0.5 MIC curcumin; 0.25 MIC AMB (or FCZ)
plus 0.75 MIC curucmin. It should be pointed out that the
sum of MICs in the above combinations was ≤ 1. Since these
combinations offered a similar or greater inhibitory effect
than 1 MIC AMB or 1 MIC FCZ, the use of these combinations not only enhanced the overall fungicidal effect but also
lowered the dosage of AMB or FCZ, which could reduce the
risk of drug-induced cytotoxicity. These advantages should
be beneficial in the treatment of candidiasis or candidemia.
An interesting finding is that 0.75 MIC AMB plus 0.25
MIC curcumin, 0.5 MIC AMB plus 0.5 MIC curcumin, and
0.25 MIC AMB plus 0.75 MIC curcumin resulted in similar
fungicidal effects; indicating these combinations resulted in

≥ 85% reduction in turbidity for C. krusei and ≥ 90% reduction in turbidity for other tested Candida species (Table 3).
As shown in Table 4, 0.25 MIC FCZ plus 0.75 MIC curcumin also offered similar inhibitory effect as 0.25 MIC AMB
plus 0.75 MIC curcumin. Accordingly, in order to decrease
the side effects of AMB (or FCZ) and to enhance the overall
fungicidal effect against these Candida species, 0.25 MIC
AMB (or FCZ) plus 0.75 MIC curcumin would be the best
choice for clinical use, since the dosage of AMB (or FCZ)
was very low.
The fungal cytotoxicity of amphotericin B is due to the
interaction of this drug with fungal membrane ergosterol
over the mammalian cell counterpart, cholesterol (6). Like
other azole compounds, the fungal cytotoxicity of fluconazole results from its binding to cytochrome p-450 molecules
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involved in the synthesis of fungal ergosterol(20,21). The failure of ergosterol synthesis then leads to the death of fungi. It
has been reported that the anti-tumor effect of curcumin was
due to the fact that this agent blocked arachidonic acid
metabolism by inhibiting cycloxygenase and/or lipoxygenase
activities(22,23). The action mode of curcumin against fungi
might be also due to its enzyme inhibitory effects, which is
apparently different from that of amphotericin B. This different action mode of curcumin from amphotericin B could
account in part for the enhanced inhibitory effect observed in
these combinations. Nevertheless, it is not the only determinant because the effect of combined therapy was not simply
additive. Further study is necessary to elucidate the fungicidal mechanism when these two agents cooperate.
Pharmacokinetic studies have indicated that following
oral administration to rats and humans, curcumin was poorly
absorbed and was transformed into metabolites during
absorption through the intestine(24). The major metabolites of
curcumin in mice are curcumin glucuronide, dihydrocurcumin glucuronide, tetrahydrocurcumin(25). It remains unknown
whether these metabolites still possess antifungal activity
like curcumin. However, the work of Shoba et al.(26) reported
that piperine (20 mg), a major component of black pepper
(Piper nigrum L.), remarkably enhanced the bioavailability
of curcumin in humans with no adverse effects. Therefore,
when curcumin is orally administrated as an antifungal agent,
the concomitant use of piperine might be considered.
Otherwise, i.v. administration of curcumin should be a better
route for its efficacy because amphotericin B or fluconazole
could be administrated via this method.
In conclusion, the combination of curcumin with
amphotericin B or fluconazole exhibited a stronger fungicidal activity than monotherapy with curcumin, amphotericin
B or fluconazole, respectively. The enhanced fungicidal
effect observed in combined therapy suggests that the interactions between curcumin and these two agents were more
than additive. These results suggest that the combined therapy of curcumin with one of these two agents may benefit the
treatment of clinical fungal infections.
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薑黃素與 Amphotericin B 或 Fluconazole 共同使用增強
抑制念珠菌之功效
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摘

要

七種院內感染的念珠菌（共 200 隻取自臨床黴菌感染病患的菌株）被使用來探討薑黃素的單獨抑菌能
力，及其與 amphotericin B 或 fluconazole 共同使用時的抑菌效果。此一共同使用時的抑菌效果以 FIC
index 及 turbidity 降低的%來表示。結果發現，薑黃素對這七種念珠菌的最低抑制濃度為 32-128 µg/mL 。
薑黃素與 amphotericin B 共同使用時則表現出加乘效果;而薑黃素與 fluconazole 共同使用時，對某些菌表
現出加乘效果，但是對某些菌卻表現出加成效果。由於薑黃素與 amphotericin B 或 fluconazole 共同使用時
可以因這些加乘或加成效果而減少 amphotericin B 或 fluconazole 的使用劑量，如此也可降低因這兩種藥物
所誘發的副作用。本研究結果支持薑黃素與 amphotericin B 或 fluconazole 共同使用將有助於院內念珠菌感
染的治療。
關鍵詞：薑黃素， amphotericin B ， fluconazole ，念珠菌

